Picture of Neuronetics logo

STIM — Neuronetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview

Neuronetics Inc <STIM.OQ> expected to post a loss of 12 cents a share - Earnings Preview 
  • Neuronetics Inc STIM.OQ STIM.O is expected to show a rise in quarterly revenue when it reports results on August 11 for the period ending June 30 2026

  • The Malvern Pennsylvania-based company is expected to report a 5.4% increase in revenue to $40.175 million from $38.11 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on May 5 2026, for the period ended June 30, was for revenue between $39.63 million and $40.39 million.

  • ​LSEG's mean analyst estimate for Neuronetics Inc is for a loss of 12 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Neuronetics Inc is $4.00, about 77.8% above its last closing price of $2.25

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Mar. 31 2026

-0.17

-0.17

-0.15

Beat

13.5

Dec. 31 2026

-0.11

-0.10

Beat

6.3

Sep. 30 2025

-0.12

-0.13

-0.13

Met

-2.6​

Jun. 30 2025

-0.07

-0.08

-0.15

Missed

-95.6

​​Mar. 31 2025

-0.13

-0.12

-0.21

Missed

-68

Dec. 31 2024

-0.25

-0.21

-0.33

Missed

-57.1​

Sep. 30 2024

-0.23

-0.23

-0.44

Missed

-91.3

Jun. 30 2024

-0.27

-0.27

-0.33

Missed

-22.2

This summary was machine generated August 7 at 16:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Neuronetics

See all news